drugset / Trial / NCT02959411

Tolvaptan for Advanced or Refractory Heart Failure

NCT02959411

Phase 4 Terminated 9 enrolled University of Calgary
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will clarify the clinical usefulness of Tolvaptan therapy in patients with complicated acute decompensated heart failure and hyponatremia (low blood sodium).

Timeline

Start
2016-10
Primary completion
2020-06-30
Completion
2020-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tolvaptan Small molecule 15 mg
Subject Tolvaptan Small molecule 60 mg

Indications